Clinical trials: Hypertension, Pulmonary Artery
Pulmonary Arterial Hypertension
Pharmacokinetics, Safety and Tolerability of Concurrent Doses of BIA 5-1058 and Furosemide
The purpose of this study is: To assess the effect of BIA 5 1058 400 mg on furosemide pharmacokinetics (PK). To assess the effect of furosemide 40 mg on the PK of BIA 5 1058.
- Trial name
- NCT07173738
- Testing
- BIA 5-1058, Furosemide, BIA 5-1058 and Furosemide
- Where
- United Kingdom
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Pulmonary Hypertension
Cardiac Magnetic Resonance Imaging and Pulmonary Perfusion
Pulmonary hypertension is a rare severe disease leading to cardiac insufficiency. Treatment depends on the severity of the disease.
- Trial name
- NCT01100008
- Testing
- Magnetic resonance imaging (MRI)
- Where
- France
- Volunteers
- 29 people
- Sponsor
- University Hospital, Toulouse
Pulmonary Arterial Hypertension
EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension
This was a multicenter, open-label study to evaluate the dose of Orenitram® (treprostinil) Extended Release Tablets achieved at 16 weeks after a short-term course of Remodulin® (treprostinil) Injection in subjects with pulmonary…
- Trial name
- NCT03497689
- Testing
- Intravenous/Subcutaneous Treprostinil; Oral Treprostinil
- Where
- 11 sites in United States
- Volunteers
- 36 people
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension
Epoprostenol for Injection in Pulmonary Arterial Hypertension - Extension of AC-066A401
This is an open-label, non-randomized extension to study AC-066A401. The study will assess safety and tolerability of ACT-385781A and Flolan (epoprostenol sodium) while providing a means for continuing treatment after ending…
- Trial name
- EPITOME-1 Ext (NCT01105117)
- Testing
- ACT-385781A (Actelion Epoprostenol), Flolan®
- Where
- 7 sites in United States
- Volunteers
- 2 people
- Sponsor
- Actelion
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Biomarkers in the Evaluation of Chronic Lung Disease
We hypothesize that hypoxia-induced pulmonary vascular remodeling is mediated by macrophage migration inhibitory factor (MIF), that remodeling is in fact the reflection of a chronic inflammatory process, and that MIF may be a…
- Conditions
- Pulmonary Hypertension, Pulmonary Arterial Hypertension, Interstitial Lung Disease
- Trial name
- NCT00926523
- Testing
- Blood Gas, Pulmonary Exercise Test, Spirometry
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Pulmonary Arterial Hypertension, Heart Defects, Congenital
The Effects of the Otago Exercise Program
The objective of this experimental study is to conduct a comparative evaluation of the effects of a supervised Otago Exercise Program (OEP) functional exercise capacity, blood lactate levels, dyspnea, fatigue, peripheral muscle…
- Trial name
- NCT06172790
- Testing
- Training
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- Istanbul University - Cerrahpasa
Hypertension, Pulmonary
Catheter Denervation of Pulmonary Arteries in Treatment of IPAH & SPAH
The aim of research proposal is to assess and compare the safety and efficacy of radiofrequency denervation of pulmonary arteries on decrease in pulmonary vascular resistance and mean pulmonary artery pressure (MPAP) in 20…
- Trial name
- CADOPA (NCT02403908)
- Testing
- nMARQ Circular and Crescent catheters
- Where
- Croatia
- Volunteers
- 60 people
- Sponsor
- Clinical Hospital Centre Zagreb
Pulmonary Arterial Hypertension
TranspulmonarY Estrogen Gradient and Estrogen Receptors (TYEGER) in PAH
Pulmonary arterial hypertension (PAH) is a disease characterized by elevated pressures in the blood vessels of the lungs that is not caused by another disease processes.
- Trial name
- TYEGER (NCT04280523)
- Testing
- ESR-specific PET scan
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Pulmonary Arterial Hypertension
Epoprostenol for Injection in Pulmonary Arterial Hypertension
This is a prospective, multi-center, open-label, randomized, Phase IV exploratory study comparing safety, tolerability, pharmacokinetics, and effectiveness of ACT-385781A and Flolan (epoprostenol sodium) in patients with…
- Trial name
- EPITOME-1 (NCT01105091)
- Testing
- ACT-385781A (Actelion Epoprostenol), Flolan®
- Volunteers
- 30 people
- Sponsor
- Actelion
Vascular Disease
Efficacy Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH)
This open label, single-arm, non-controlled, multicentre study will determine the effect of ambrisentan on exercise capacity (6MWT) in Chinese subjects with PAH.
- Trial name
- NCT01808313
- Testing
- ambrisentan
- Where
- 12 sites in China
- Volunteers
- 134 people
- Sponsor
- GlaxoSmithKline
Pulmonary Arterial Hypertension
A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension
This study evaluates the effect of sotatercept (ACE-011) in adults with pulmonary arterial hypertension (PAH). Each eligible participant will receive standard of care (SOC) plus sotatercept (ACE-011) for a 24-week treatment…
- Trial name
- SPECTRA (NCT03738150)
- Testing
- Sotatercept, SOC
- Where
- 4 sites in United States
- Volunteers
- 21 people
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Safety and Effectiveness of PRX-08066 in Patients With Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease
This study is being conducted to see if PRX-08066 can lower pulmonary artery pressures in patients with pulmonary hypertension associated with chronic obstructive pulmonary disease.
- Trial name
- NCT00345774
- Testing
- PRX-08066
- Where
- 19 sites in United States
- Volunteers
- 72 people
- Sponsor
- Epix Pharmaceuticals, Inc.
Pulmonary Hypertension
Losartan Therapy in Pulmonary Hypertension
In addition to being effective vasodilators, angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) exert neurohumoral inhibitory actions, such as the inhibition of vascular remodeling and…
- Trial name
- NCT00519870
- Testing
- nifedipine, losartan, losartan
- Sponsor
- Baskent University
Myocardial Dysfunction, Endothelial Dysfunction
Bosentan in Myocardium Metabolism and Perfusion Measured by 18F-FDG and 82Rb PET/CT on PAH and CTEPH
The purpose of this study is to assess the effect of bosentan on the myocardial metabolism and the dependent endothelial coronary vasomotoricity in patients presenting a PAH.
- Trial name
- NCT02970851
- Where
- Switzerland
- Volunteers
- 2 people
- Sponsor
- University of Lausanne Hospitals
Hypertension, Pulmonary Arterial Hypertension
Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension
The main purpose of this clinical trial is to examine the feasibility and effects of tamoxifen in subjects with pulmonary arterial hypertension (PAH).
- Conditions
- Hypertension, Pulmonary Arterial Hypertension, Familial Primary Pulmonary Hypertension, Primary Pulmonary Hypertension
- Trial name
- T3PAH (NCT03528902)
- Testing
- Tamoxifen
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Vanderbilt University Medical Center
Pulmonary Arterial Hypertension
Algorithms to Diagnose Pulmonary Arterial Hypertension
The investigators intend to evalute the value of radiomics signature of pulmonary vessels from chest computed tomography (CT) for dianosis and prognosis of pulmonary arterial hypertension.
- Trial name
- NCT05417373
- Testing
- calculated radscore
- Where
- China
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- RenJi Hospital
Pulmonary Arterial Hypertension
A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)
The objectives of this study are to evaluate the efficacy and safety of sotatercept (MK-7962) treatment (plus background pulmonary arterial hypertension (PAH) therapy) versus placebo (plus background PAH therapy) at 24 weeks in…
- Trial name
- NCT04576988
- Testing
- Sotatercept, Background PAH Therapy
- Where
- 120 sites in United States, Argentina and 19 more
- Volunteers
- 324 people
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Healthy
Multiple-Ascending Dose in Japanese Patients Bridging Study
This study is a randomized, placebo-controlled, multiple-ascending dose study in healthy Japanese and Caucasian subjects.
- Trial name
- NCT05065359
- Testing
- Rodatristat Ethyl 300 mg BID, Rodatristat Ethyl 600 mg BID
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Altavant Sciences GmbH
Pulmonary Arterial Hypertension
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension
The main objective of the study is to assess the effect of treprostinil palmitil inhalation powder (TPIP) compared with placebo on pulmonary vascular resistance.
- Trial name
- NCT05147805
- Testing
- Treprostinil Palmitil
- Where
- 92 sites in United States, Argentina and 15 more
- Volunteers
- 102 people
- Sponsor
- Insmed Incorporated
Pulmonary Arterial Hypertension
FDG Uptake and Lung Blood Flow in PAH Before and After Treatment With Ambrisentan
The investigators are doing this research study to find out how blood flow changes in the lungs of people with pulmonary hypertension before and after treatment with ambrisentan (sold under the brand name Letairis).
- Trial name
- NCT02958358
- Testing
- CT imaging, functional PET imaging
- Where
- United States
- Sponsor
- Robert Scott Harris, M.D.